Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521638 | 0.86 | HRH4 (0.53) | KMT2AL3MBTL1SMN1; SMN2KDM4EGAA | |
| SCHEMBL2378215 | 0.86 | KMT2A (0.75) | KMT2AL3MBTL1SMN1; SMN2KDM4EGAA | |
| SCHEMBL16982448 | 0.84 | ALDH1A1 (0.56) | KMT2AL3MBTL1SMN1; SMN2KDM4EGAA | |
| SCHEMBL7459206 | 0.83 | SMN1; SMN2 (0.55) | KMT2AL3MBTL1SMN1; SMN2KDM4EGAA | |
| SCHEMBL12260740 | 0.82 | KMT2A (0.60) | KMT2AL3MBTL1SMN1; SMN2KDM4EGAA | |
| SCHEMBL4893361 | 0.82 | KMT2A (0.60) | KMT2AL3MBTL1SMN1; SMN2KDM4EGAA | |
| SCHEMBL4115804 | 0.81 | PKM (0.60) | KMT2AL3MBTL1SMN1; SMN2KDM4EGAA | |
| SCHEMBL17749697 | 0.81 | KMT2A (0.58) | KMT2AL3MBTL1SMN1; SMN2KDM4EGAA | |
| SCHEMBL30073534 | 0.81 | KMT2A (0.58) | KMT2AL3MBTL1SMN1; SMN2KDM4EGAA | |
| SCHEMBL13883807 | 0.80 | ALDH1A1 (0.66) | KMT2ASMN1; SMN2KDM4EGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531668-B2 | 2-arylcarboxamide-nitrogenous heterocycle compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20070299070-A1 | 2-Arylcarboxamide-Nitrogenous Heterocycle Compound | MSD K.K. (JP) | 2007-12-27 | — | — | US | disclosed |
| EP-1798221-A1 | 2-ARYLCARBOXAMIDE-NITROGENEOUS HETEROCYCLE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299070-A1 | 2-Arylcarboxamide-Nitrogenous Heterocycle Compound | MCHR2, MCHR1, NPY2R | KMT2A 1019/4885L3MBTL1 2581/4885SMN1; SMN2 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.